Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China's Sinovac Sees Profits Plummet In Wake Of Public Fears Following Vaccine Scandals By Other Producers

This article was originally published in PharmAsia News

Executive Summary

BEIJING - China's leading vaccine developer, Sinovac Biotech, posted a steep fall in profits for the second quarter, and revealed that the World Health Organization is working with Chinese regulators on monitoring good manufacturing practice standards following a series of scandals that have hurt the entire sector
Advertisement

Related Content

Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?
Bill Gates Meets With Sinovac Scientists In Beijing: Will They Be Integrated Into Gates Foundation's Global Immunization Drives?
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
GSK Channels More Money Into Vaccine Venture With China's Neptunus As Earnings Sink In The West
Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner
CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red
CEO Of China's Leading Vaccine Producer Reveals Latest Vaccine Scandal Has Triggered A Sector-wide Boycott, Throwing Firm Into The Red
Advertisement
UsernamePublicRestriction

Register

SC075666

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel